All In Biotech

Drug Trial Radar · NCT02704858

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

49

Planned (sponsor's estimate)

Start

Aug 1, 2017

Primary completion

Nov 30, 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Neonc Technologies, Inc.Industry
Sponsor type
Industry
First posted
Mar 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will be up to 24 patients enrolled in Phase 1. There will be 25 patients enrolled in Phase 2a. For both phases of the study, NEO100 will be self-administered four times daily for a 28-day treatment cycles until disease progression, death or patient withdraw from study for any reason, whichever occurs first. Version 10 of the protocol changed the inclusion criteria for Phase 2a to limit inclusion to those patients with progressive or recurrent primary or secondary Grade IV gliomas expressing IDH1 mutations. Prior to the protocol amendment, 4 patients were enrolled who were IDH1 wild-type. Therefore, an additional 28 patients will be recruited for a total of 32 patients enrolled into Phase 2a of this study to have 35 evaluable cases. Version 12 of the protocol expanded the inclusion criteria for Phase 2a to include those patients with progressive or recurrent Grade III Astrocytoma expressing IDH1 mutations. Review of the literature specific to these patients found the same expected time to progression and death. As a result, the number of patients to enroll remains 32 to have 35 evaluable cases.

Conditions

  • Glioblastoma Multiforme

Interventions

  • Perillyl alcoholDrug

    Intranasal administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: Up to 6 months
  2. Phase 2 Primary Outcome: Number of Participants Who Are Alive Each Month For 6 MonthsTime frame: Up to 6 months
  3. Phase 2 Primary Outcome: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related To TreatmentTime frame: 6 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • Sutter Health Research Institute

    San Francisco, California

  • Saint John Cancer Institute

    Santa Monica, California

  • Georgia Cancer Center (Augusta University)

    Augusta, Georgia

  • Ochsner Health

    New Orleans, Louisiana

  • Atlantic Health (Overlook Medical Center)

    Summit, New Jersey

  • Northwell Health

    New York, New York

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Baylor Scott & White Health

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.